Free Pre-Market Technical Recap on ArQule and Three Additional Biotech

Stock Research Monitor: ARNA, ARWR, and ATRA

LONDON, UK / ACCESSWIRE / July 12, 2018 / If you want a free Stock Review on ARQL sign up now at www.wallstequities.com/registration. On Wednesday, July 11, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Eight out of nine sectors ended Wednesday's trading session in bearish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), ArQule Inc. (NASDAQ: ARQL), Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR), and Atara Biotherapeutics Inc. (NASDAQ: ATRA). All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

Arena Pharmaceuticals

On Wednesday, shares in San Diego, California-based Arena Pharmaceuticals Inc. recorded a trading volume of 357,565 shares. The stock ended at $43.82, declining 0.97% from the last trading session. The Company's shares have gained 21.05% over the previous three months and 68.54% in the last twelve months. The stock is trading above its 200-day moving average by 19.45%. Furthermore, shares of Arena Pharma, which focuses on developing novel small molecule drugs for various therapeutic areas in the US and Switzerland, have a Relative Strength Index (RSI) of 42.83. Get the full research report on ARNA for free by clicking below at:

www.wallstequities.com/registration/?symbol=ARNA

ArQule

Burlington, Massachusetts headquartered ArQule Inc.'s stock finished yesterday's session 4.07% lower at $5.90. A total volume of 6.83 million shares was traded, which was above their three months average volume of 1.79 million shares. The Company's shares have gained 11.74% in the last month, 107.02% over the previous three months, and 357.36% in the last twelve months. The stock is trading above its 50-day and 200-day moving averages by 31.47% and 143.02%, respectively. Furthermore, shares of ArQule, which researches and develops therapeutics for the treatment of cancer and rare diseases in the US, have an RSI of 59.15.

On June 18^th, 2018, research firm Needham reiterated its ‘Buy' rating on the Company's stock with an increase of the target price from $6 a share to $7 a share. To experience our free membership services anytime/ anywhere and access the free report on ARQL, click to register at:

www.wallstequities.com/registration/?symbol=ARQL

Arrowhead Pharmaceuticals

At the close of trading on Wednesday, shares in Pasadena, California headquartered Arrowhead Pharmaceuticals Inc. saw a rise of 1.92%, ending the day at $16.42. The stock recorded a trading volume of 1.41 million shares. The Company's shares have advanced 47.79% in the last month, 127.11% in the previous three months, and 973.20% over the last twelve months. The stock is trading above its 50-day and 200-day moving averages by 47.91% and 147.86%, respectively. Moreover, shares of Arrowhead Pharma, which develops medicines for the treatment of intractable diseases in the US, have an RSI of 77.48.

On July 02^nd, 2018, research firm Chardan Capital Markets reiterated its ‘Buy' rating on the Company's stock with an increase of the target price from $9.50 a share to $16 a share. Join our big investor community at Wall St. Equities today and get your free report on ARWR at:

www.wallstequities.com/registration/?symbol=ARWR

Atara Biotherapeutics

South San Francisco, California headquartered Atara Biotherapeutics Inc.'s shares ended the day 0.99% higher at $40.65 with a total trading volume of 380,293 shares. The stock has gained 186.27% over the last twelve months. The Company's shares are trading above their 200-day moving average by 30.27%. Additionally, shares of Atara Biotherapeutics, which develops treatments for patients with cancer, autoimmune, and viral diseases in the US, have an RSI of 47.14. Know more about ATRA in our free research coverage at:

www.wallstequities.com/registration/?symbol=ATRA

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com

Phone number: 21 32 044 483

Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities